department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

ONO-4578 · pharmadog

pharmadog
drugs
ONO-4578

drug · small molecule

patient view →

ONO-4578

Phase 2updated 2mo ago

by Bristol-Myers Squibb Co🔗 ChEMBL

Phase 2

community read0 votes

Small molecule drug with a maximum clinical stage of Phase 1 (across all indications), with 2 investigational indications.

all catalysts(1)

phase 1 completion · 1

phase 1 completion

Ono Pharmaceutical Co Ltd — ONO-4578 (Phase I Trial Completion)

News(0)

no news has mentioned this drug yet

indication

Metastatic Colorectal Cancer

phase

phase_2

Data sources

ClinicalTrials.gov · OpenTargets

last refreshed 1h ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

🐶 often sniffed alongside

top 4

tagOncology6 co-mentions · 1 sources
tagBreast Cancer5 co-mentions · 1 sources
companyOno Pharmaceutical Co Ltd1 co-mentions · 1 sources
tagHER21 co-mentions · 1 sources

Trials studying ONO-4578

phase2A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancerrecruitingn=144
phase2A Study to Investigate the Efficacy and Safety of ONO-4578 in Combination With Nivolumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)active not recruitingn=226
phase1ONO-4578-06:Phase I Study of ONO-4578 and Letrozole Plus CDK4 /6 Inhibitors in Breast Canceractive not recruitingn=46
phase1Study of ONO-4578 With and Without ONO-4538 in Subjects Advanced or Metastatic Solid Tumorsactive not recruitingn=183
phase1An Open-label, Uncontrolled Study of ONO-4578 and ONO-4538 in Combination With Standard-of-care Modified FOLFIRINOX (mFFX) or Gemcitabine Plus Nab-paclitaxel (GnP) Therapy as First-line Treatment in Patients With Metastatic Pancreatic Cancercompletedn=46
phase1Study of ONO-4578 and XELOX/FOLFOX Plus Bevacizumab in Colorectal Canceractive not recruitingn=40
phase1An Open-label, Uncontrolled Study of ONO-4578 and ONO-4538 in Combination With Standard-of-care Docetaxel and Ramucirumab as Second-line Therapy in Patients With Advanced or Recurrent Non-small Cell Lung Canceractive not recruitingn=42